Conference Details - Agenda
View all Conferences
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
13th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas
The Fairmont Château Whistler
Whistler, British Columbia, Canada
February 11-15, 2009
| 12:00 pm |
Registration
|
| 4:00 pm |
Welcome and Introductions
|
| 4:05 pm |
Keynote Lecture: Victories and Challenges in Hodgkin Disease
Joseph M. Connors |
| 4:50 pm |
Chronic Lymphocytic Leukemia
John C. Byrd |
| 5:05 pm |
Multiple Myeloma
Sundar Jagannath |
| 5:20 pm |
Indolent Lymphoma
George G. Weiner |
| 5:35 pm |
Acute Myeloid Leukemia
Martin S. Tallman |
| 5:50 pm |
Chronic Myeloid Leukemia
Charles Schiffer |
| 6:05 pm |
Aggressive Lymphoma
Andrew D. Zelenetz |
| 6:20 pm |
Panel Discussion
|
| 6:40 pm |
Adjourn
|
| 7:00 pm-8:00 pm |
Reception
|
| 6:30 am |
Continental Breakfast
|
| 7:00 am |
Keynote Lecture: What Pathologic Prognostic Markers Can Be Helpful in B-Cell Lymphomas?
Randy Gascoyne |
| 7:30 am |
Presession Survey
|
| 7:40 am |
How Will I Treat First-line Follicular Lymphoma?
Jonathan Friedberg |
| 7:55 am |
How Will I Treat Marginal Zone/MALT Lymphoma?
Joseph M. Connors |
| 8:10 am |
How Will I Treat CNS Lymphoma?
James Rubenstein |
| 8:25 am |
Question-and-Answer Session
|
| |
Debate 1: Management of Limited-Stage Follicular Lymphoma—Radiation Versus Systemic Therapies
|
| 8:35 am |
Radiation Therapy
Joseph M. Connors |
| 8:50 am |
Systemic Therapy
Fredrick Hagemeister, Jr |
| 9:05 am |
Rebuttal
Joseph M. Connors |
| 9:10 am |
Panel Discussion
|
| |
Debate 2: Intensive Versus Nonintensive Therapies in Mantle Cell Lymphoma
|
| 9:20 am |
Intensive
Andrew D. Zelenetz |
| 9:35 am |
Nonintensive
Sven de Vos |
| 9:50 am |
Rebuttal
Andrew D. Zelenetz |
| 9:55 am |
Panel Discussion
|
| 10:05 am |
Postsession Survey
|
| 10:15 am |
Adjourn
|
| 10:40 am |
Syk Inhibitors
Jonathan Friedberg |
| 10:55 am |
Anti–BCL-2 Strategies
Wyndham H. Wilson |
| 11:10 am |
mTOR Inhibitors
Sonali M. Smith |
| 11:25 am |
Question-and-Answer Session
|
| 11:35 am |
Novel Anti-CD20 Antibodies
Fredrick Hagemeister |
| 11:50 am |
Other Non–Anti-CD20 Antibodies
George G. Weiner |
| 12:05 pm |
Question-and-Answer Session
|
| 12:15 pm |
Adjourn
|
| 4:00 pm |
Presession Survey
|
| 4:10 pm |
Management of Nodal T-Cell Lymphoma
Barbara Pro |
| 4:30 pm |
Emerging Treatment Options for Cutaneous T-Cell Lymphoma
Madeleine Duvic |
| 4:50 pm |
Question-and-Answer Session
|
| 5:00 pm |
Panel Discussion: Clinical Problems in Oncology—Prognosis, Risk Stratification, and Treatment of Diffuse Large B-Cell Lymphoma
Randy Gascoyne, Wyndham H. Wilson, Andrew D. Zelenetz |
| |
Debate 3: Promise and Pitfalls Regarding State-of-the-Art Treatment of Elderly Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
|
| 6:00 pm |
Promising Data
Paul Hamlin |
| 6:15 pm |
Pitfall Analysis
Michael Pfreundschuh |
| 6:30 pm |
Rebuttal
Paul Hamlin |
| 6:35 pm |
Panel Discussion and Postsession Survey
|
| 7:00 pm |
Adjourn
|
| 6:20 am |
Continental Breakfast/Meet the Professors
|
| 7:00 am |
Presession Survey
|
| 7:10 am |
Keynote Lecture: Management of Essential Thrombocythemia, Polycythemia Vera, and Myeloid Metaplasia
Jerry Spivak |
| 7:40 am |
Less Common Myeloproliferative Disorders, Including Hypereosinophilic Syndromes and Mastocytosis
Ruben A. Mesa |
| 8:05 am |
Question-and-Answer Session
|
| 8:15 am |
Monitoring Response to Treatment in Chronic Myeloid Leukemia
Harry Erba |
| 8:40 am |
Treatment of Imatinib-Resistant Chronic Myeloid Leukemia
Charles Schiffer |
| 9:05 am |
Chronic Myeloid Leukemia Drugs on the Horizon
Michael W. N. Deininger |
| 9:30 am |
Question-and-Answer Session
|
| 9:40 am |
Postsession Survey and Case-Based Panel Discussion
|
| 10:00 am |
Adjourn
|
| 10:30 am |
New Agents for Hairy Cell Leukemia
Charles Schiffer |
| 10:50 am |
New Agents for Older Patients With Acute Myeloid Leukemia
Harry Erba |
| 11:10 am |
Current State of BCL-2 Inhibitors
Michael W. N. Deininger |
| 11:25 am |
Question-and-Answer Session
|
| 11:35 am |
JAK2 Inhibitors
Ruben A. Mesa |
| 11:50 am |
Looking Beyond the "Nibs": New Agents for Chronic Myeloid Leukemia
Charles Schiffer |
| 12:05 pm |
Question-and-Answer Session
|
| 12:15 pm |
Adjourn
|
| 4:00 pm |
Presession Survey
|
| 4:05 pm |
The Use of Reduced-Intensity Conditioning for Older Adults
Jerald P. Radich |
| 4:25 pm |
Management of Acute Lymphoblastic Leukemia in Adults
Wendy Stock |
| 5:05 pm |
Question-and-Answer Session
|
| 5:15 pm |
Management of Early-Stage Myelodysplastic Syndromes
David Steensma |
| 5:35 pm |
Where Do We Stand With the Use of Hypomethylating Agents? Results From Recent Trials
Jamile M. Shammo |
| 5:55 pm |
Question-and-Answer Session
|
| 6:05 pm |
Postsession Survey
|
| |
Debate 4: Transplantation Is a More Appropriate Option Than Chemotherapy for Patients With Acute Myeloid Leukemia in First Complete Response
|
| 6:10 pm |
PRO
Charles Schiffer |
| 6:25 pm |
CON
Jerald P. Radich |
| 6:40 pm |
Rebuttal
Charles Schiffer |
| 6:45 pm |
Question-and-Answer Session
|
| 6:55 pm |
Case-Based Panel Discussion
|
| 7:15 pm |
Adjourn
|
| 6:20 am |
Continental Breakfast/Meet the Professors
|
| 7:00 am |
Keynote Lecture: Cancer Stem Cells in Multiple Myelomas
Linda Pilarski |
| 7:30 am |
Presession Survey
|
| 7:40 am |
Where Is the Real Progress in Multiple Myeloma?
James Berenson |
| 8:00 am |
Moving Toward Individualized Medicine for Multiple Myeloma
Sagar Lonial |
| 8:20 am |
Case-Based Panel Discussion
|
| 8:35 am |
Is Complete Response the Goal of Initial Therapy?
Sundar Jagannath |
| 8:55 am |
Sequencing of Targeted Agents in Relapsed/Refractory Multiple Myeloma
Sundar Jagannath |
| 9:15 am |
Case-Based Panel Debate: Transplant Now or Later?
Donna Reece |
| 9:35 am |
Curbside Strategies: Audience-Generated Consultations
|
| 9:50 am |
Postsession Survey
|
| 10:00 am |
Adjourn
|
| 10:30 am |
Histone Deacetylase Inhibitors
James Berenson |
| 10:45 am |
Novel Proteasome Inhibitors
Jatin Shah |
| 11:00 am |
CDK Inhibitors
Thomas Lin |
| 11:15 am |
Question-and-Answer Session
|
| 11:25 am |
HSP90 Inhibitors
Jeffrey Zonder |
| 11:40 am |
Novel Immunomodulatory Agents
Jeffrey Zonder |
| 11:55 am |
Question-and-Answer Session
|
| 12:10 pm |
Adjourn
|
| 4:00 pm |
Keynote Lecture: New Developments in the Molecular Biology of Chronic Lymphocytic Leukemia
Thomas James Kipps |
| 4:30 pm |
Presession Survey
|
| 4:40 pm |
Decision Points in Treating a Patient With Newly Diagnosed Chronic Lymphocytic Leukemia
Thomas Lin |
| 5:00 pm |
Update on Management Strategies for Relapsed/Refractory Chronic Lymphocytic Leukemia
John C. Byrd |
| 5:20 pm |
Novel Approaches to Treating Elderly Patients With Chronic Lymphocytic Leukemia
Alessandra Ferrajoli |
| 5:40 pm |
Panel Discussion
|
| |
Debate 5: Purine Analogue of Choice for Use in Standard Regimens—Pentostatin Versus Fludarabine
|
| 6:00 pm |
Pentostatin
Michael R. Grever |
| 6:15 pm |
Fludarabine
William G. Wierda |
| 6:30 pm |
Rebuttal
|
| 6:35 pm |
Panel Discussion
|
| 6:55 pm |
Postsession Survey
|
| 7:05 pm |
Adjourn
|
| 6:30 am |
Continental Breakfast
|
| 7:00 am |
Acute Leukemias
Harry Erba |
| 7:20 am |
Keynote Lecture: Supportive Care in Hematologic Malignancies
Sundar Jagannath |
| 7:50 am |
Idiopathic Thrombocytopenic Purpura
Morey Blinder |
| 8:20 am |
Relapsed Myeloma
Sagar Lonial |
| 8:40 am |
Burkitt Lymphoma
Andrew D. Zelenetz |
| 9:00 am |
Hodgkin Disease
Frederick Hagemeister, Jr |
| 9:20 am |
Closing Remarks
|
| 9:30 am |
Adjourn
|
